Protalix BioTherapeutics (PLX) Capital Expenditures Growth (5y) (2015 - 2026)
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn |
| 10 | Protalix BioTherapeutics | 164.49 Mn | 153.70 Mn | 29.62 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -5.82% |
| Dec 31, 2025 | -68.90% |
| Sep 30, 2025 | 37.32% |
| Jun 30, 2025 | 7.90% |
| Mar 31, 2025 | 45.27% |
| Dec 31, 2024 | -3.78% |
| Sep 30, 2024 | 13.43% |
| Jun 30, 2024 | -71.63% |
| Mar 31, 2024 | 28.60% |
| Dec 31, 2023 | 27.14% |
| Sep 30, 2023 | -31.37% |
| Jun 30, 2023 | 7.07% |
| Mar 31, 2023 | -0.08% |
| Dec 31, 2022 | -17.23% |
| Sep 30, 2022 | -2.12% |
| Jun 30, 2022 | -19.71% |
| Mar 31, 2022 | 0.81% |
| Dec 31, 2021 | 30.80% |
| Sep 30, 2021 | 16.99% |
| Jun 30, 2021 | -2.81% |
| Mar 31, 2021 | 8.99% |
| Dec 31, 2020 | -77.76% |
| Sep 30, 2020 | -4.44% |
| Jun 30, 2020 | -1.87% |
| Mar 31, 2020 | -7.79% |
| Mar 31, 2019 | -8.36% |
| Dec 31, 2018 | -26.43% |
| Sep 30, 2018 | -20.48% |
| Jun 30, 2018 | -26.99% |
| Mar 31, 2018 | -17.26% |
| Dec 31, 2017 | 2.93% |
| Sep 30, 2017 | -29.09% |
| Jun 30, 2017 | 6.39% |
| Mar 31, 2017 | -22.95% |
| Dec 31, 2016 | -30.16% |
| Sep 30, 2016 | -30.74% |
| Jun 30, 2016 | -25.50% |
| Mar 31, 2016 | -37.37% |
| Dec 31, 2015 | -67.11% |
| Sep 30, 2015 | -37.51% |